Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom, ArcticDx Settle IP Litigation

NEW YORK (GenomeWeb News) – Sequenom and ArcticDx have settled their IP dispute, Sequenom disclosed in its Form 10-Q filed on Thursday.

The firms have reached a settlement agreement and are asking the US District Court, Eastern District of Texas Marshall Division to dismiss the lawsuit filed by ArcticDx earlier this year, Sequenom said in its document filed with the US Securities and Exchange Commission.

The disputed patents relate to adult macular degeneration testing technology.

In the lawsuit, Canadian molecular diagnostics firm ArcticDx accused Sequenom and its Sequenom Center for Molecular Medicine subsidiary of infringing US Patent 8,114,592, licensed by ArcticDx from Cambridge Enterprise. It also asked the court to find that it did not infringe on five patents held by Sequenom — US Patents 8,053,190; 7,867,727; 7,695,909; 7,351,524; and 8,088,579.

Terms of the settlement were not disclosed. Sequenom said that the terms of the settlement are "immaterial" to its financial position, liquidity, and results of operations.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.